Hyderabad: Dr Reddy’s Laboratories Ltd, India’s second biggest drug maker by sales, on Thursday said it has launched zoledronic acid injection in the US market following approval by the US Food and Drug Administration.

The medicine, used to treat osteoporosis in women after menopause, is a generic version of Swiss pharmaceutical company Novartis AG’s Reclast (zoledronic acid) injection.

The Reclast brand had total US sales of approximately $355 million for the most recent 12 months ending February, according to US-based healthcare information provider IMS Health.

Dr. Reddy’s zoledronic acid injection is available in a single use vial for intravenous infusion.

Shares of Dr.Reddy’s gained by 3.03% to close at Rs.1,890.40 on the BSE while the benchmark Sensex declined by 1.55% to 18,509.70 points.